Syk

R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.

R935788 (Fostamatinib disodium) is a potent orally available inhibitor of Syk that inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.

R788 (Fostamatinib) is an important spleen tyrosine kinase (Syk) inhibitor, showing efficacy against kinase-mediated IgG Fc gamma receptor signaling.

P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.

Piceatannol is an anti-inflammatory, immunomodulatory and antiproliferative agent. Inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-??B activation and gene expression.

PRT2607, also known as PRT062607, P505-15, and BIIB057, is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.

GS-9973 is an oral inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity.

R112 is a Syk inhibitor. R112 inhibited degranulation induced by anti-IgE cross-linking in mast cells and also blocked leukotriene C4 production and all proinflammatory cytokines tested.

PRT-060318 is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment.

MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.

RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.

Fostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.

TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.